Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CLK3 | P49761 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560941 | 0.88 | PIM1 (0.52) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL11929477 | 0.86 | PIM1 (0.54) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL1560884 | 0.86 | PIM1 (0.46) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL13190544 | 0.85 | PIM1 (0.52) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL1561016 | 0.84 | PIM1 (0.45) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL2217130 | 0.84 | PIM1 (0.48) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL1559829 | 0.84 | PIM1 (0.43) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL1560592 | 0.83 | FYN (0.46) | PIM1PIM2PIM3FYNWNT1 | |
| SCHEMBL1560893 | 0.82 | PIM1 (0.47) | PIM1PIM2PIM3WNT1CHEK1 | |
| SCHEMBL1561166 | 0.82 | PIM1 (0.43) | PIM1PIM2PIM3WNT1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | claimed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | PIM1 2969/4885PIM2 3258/4885PIM3 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.